Iopromide
Clinical data | |
---|---|
Trade names | Ultravist |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Pregnancy category |
|
Routes of administration | Intravascular |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ~1% |
Metabolism | None |
Elimination half-life | 2 hours |
Excretion | Kidneys |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.070.330 |
Chemical and physical data | |
Formula | C18H24I3N3O8 |
Molar mass | 791.116 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Iopromide is an iodinated contrast medium for X-ray imaging. It is marketed under the name Ultravist which is produced by Bayer Healthcare. It is a low osmolar, non-ionic contrast agent for intravascular use; i.e., it is injected into blood vessels.[2]
It is commonly used in radiographic studies such as intravenous urograms, brain computer tomography (CT)[2] and CT pulmonary angiograms (CTPAs).
Medical uses
[edit]The radiocontrast agent is given intravenously in computed tomography (CT) scans, angiography and excretory urography.[3]
Contraindications
[edit]Iopromide use is contraindicated in myelography, cerebral ventriculography and cisternography procedures. It is also contraindicated in those with hyperthyroidism, or with known allergy to the drug.[4]
Iopromide is also contraindicated in children with prolonged fasting, fluid restriction, on laxative, or dehydration as it can cause renal failure.[4]
References
[edit]- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ a b Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Ultravist 300 mg J/ml-Infusionsflaschen.
- ^ "Prescribing information - Ultravist" (PDF). Bayer Healthcare pharmaceuticals. Archived from the original (PDF) on 10 April 2021.
- ^ a b "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ULTRAVIST® Iopromide Injection" (PDF). Bayer Healthcare Pharmaceuticals. Archived from the original (PDF) on 27 October 2021. Retrieved 16 April 2024.